Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 1/20 | 0.64 |
| ▸ | MIF | P14174 | 11/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 4/20 | 0.61 |
| ▸ | GLA | P06280 | 4/20 | 0.61 |
| ▸ | GAA | P10253 | 4/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | HPGD | P15428 | 4/20 | 0.61 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.61 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.61 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | CA9 | Q16790 | 2/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | FLT3 | P36888 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5296804 | 0.81 | HSD17B3 (0.68) | HSD17B3MIFKDM4EMEN1GLA | |
| SCHEMBL16085333 | 0.81 | SMN1; SMN2 (0.63) | HSD17B3MIFKDM4EMEN1GLA | |
| SCHEMBL31672162 | 0.78 | POLB (0.59) | HSD17B3MIFKDM4EMEN1GLA | |
| SCHEMBL10789981 | 0.78 | HSD17B3 (0.64) | HSD17B3MIFKDM4EMEN1GLA | |
| SCHEMBL10794401 | 0.78 | HSD17B3 (0.64) | HSD17B3MIFKDM4EMEN1GLA | |
| SCHEMBL126040 | 0.78 | HSD17B3 (1.00) | HSD17B3MIFKDM4EMEN1GLA | |
| SCHEMBL10791318 | 0.78 | MIF (0.65) | HSD17B3MIFKDM4EMEN1GLA | |
| SCHEMBL8755758 | 0.78 | POLB (0.59) | HSD17B3MIFALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL18141852 | 0.77 | POLB (0.59) | HSD17B3MIFKDM4EMEN1GLA | |
| SCHEMBL893210 | 0.77 | MEN1 (0.74) | HSD17B3MIFKDM4EMEN1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117777926-A | Photo-induced moisture-curable polyurethane hot melt adhesive easy to repair and preparation method thereof | 烟台德邦科技股份有限公司 | 2024-03-29 | — | — | CN | claimed |
| CN-112574280-B | Double-enzyme system probe and application thereof | 北京大学第一医院 | 2022-05-17 | — | — | CN | claimed |
| CN-112574280-A | Double-enzyme system probe and application thereof | 北京大学第一医院 | 2021-03-30 | — | — | CN | claimed |
| CN-105693674-B | A kind of preparation and application of cumarin luminophor | 安徽工业大学 | 2018-01-09 | — | — | CN | claimed |
| CN-102519949-A | Naked eye visual colorimetric method-based probe for detecting nickel ions and preparation method and applications thereof | UNIV JIANGNAN | 2012-06-27 | — | — | CN | claimed |
| CN-119823085-A | 3-Warfarin compounds and application thereof | 济南尚诚医药科技有限公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-117777926-A | Photo-induced moisture-curable polyurethane hot melt adhesive easy to repair and preparation method thereof | 烟台德邦科技股份有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-117777926-A | Photo-induced moisture-curable polyurethane hot melt adhesive easy to repair and preparation method thereof | 烟台德邦科技股份有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-115161014-B | Preparation method and application of doped room temperature phosphorescent waterborne polymer anti-counterfeiting material | 昆明理工大学 | 2023-04-07 | — | — | CN | disclosed |
| CN-115161014-A | Preparation method and application of doped room temperature phosphorescent waterborne polymer anti-counterfeiting material | 昆明理工大学 | 2022-10-11 | — | — | CN | disclosed |
| CN-112574280-B | Double-enzyme system probe and application thereof | 北京大学第一医院 | 2022-05-17 | — | — | CN | disclosed |
| CN-112574280-A | Double-enzyme system probe and application thereof | 北京大学第一医院 | 2021-03-30 | — | — | CN | disclosed |
| US-7411076-B2 | such as 2-chloro-N-(7-hydroxy-2-oxo-2H-1-benzopyran-3-yl)benzamide, used for intensifying the effects of cancer therapy based on DNA injury; protein kinase inhibitors; side effect reduction | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-08-12 | — | — | US | disclosed |
| US-7411076-B2 | such as 2-chloro-N-(7-hydroxy-2-oxo-2H-1-benzopyran-3-yl)benzamide, used for intensifying the effects of cancer therapy based on DNA injury; protein kinase inhibitors; side effect reduction | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-08-12 | — | — | US | disclosed |
| US-7411076-B2 | such as 2-chloro-N-(7-hydroxy-2-oxo-2H-1-benzopyran-3-yl)benzamide, used for intensifying the effects of cancer therapy based on DNA injury; protein kinase inhibitors; side effect reduction | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-08-12 | — | — | US | disclosed |
| US-20070270452-A1 | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-11-22 | — | — | US | disclosed |
| EP-1807440-A2 | NOVOBIOCIN ANALOGUES AS ANTICANCER AGENTS | The University of Kansas (US) | 2007-07-18 | — | — | EP | disclosed |
| US-20060199776-A1 | Novobiocin analogues as anticancer agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-09-07 | — | — | US | disclosed |
| WO-2006050501-A2 | NOVOBIOCIN ANALOGUES AS ANTICANCER AGENTS | UNIVERSITY OF KANSAS (US) | 2006-05-11 | — | — | WO | disclosed |
| US-20050054717-A1 | Coumarin derivative | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270452-A1 | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders | SSB, IAPP, NLN | HSD17B3 2831/4885MIF 4585/4885KDM4E 4719/4885 |
| US-20060199776-A1 | Novobiocin analogues as anticancer agents | HSP90B1, HSP90AB2P, HSP90AB1 | HSD17B3 3583/4885MIF 2931/4885KDM4E 4084/4885 |
| US-20050054717-A1 | Coumarin derivative | ERCC2, ERCC4, DDB1 | HSD17B3 1531/4885MIF 1111/4885KDM4E 3979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.